Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Estrogen has been shown to upregulate endogenous MOTS-c expression in preclinical models, which may partly explain why metabolic deterioration accelerates in perimenopause when estrogen falls precipitously [2]
While topical application has minimal systemic absorption, the precautionary principle suggests avoiding use during pregnancy unless a healthcare provider approves
Route Published human studies mainly used oral and intravenous forms
Your honest opinion helps others make better choices
Based on current clinical evidence, the rough ordering from largest to smallest weight-loss effect is: Tirzepatide highest average weight loss Semaglutide significant weight loss Tesamorelin moderate weight loss, primarily through visceral fat reduction AOD-9604 primarily body composition effects MOTS-c primarily metabolic and energy effects rather than pure weight reduction AOD-9604 and MOTS-c are generally not considered replacements for GLP-1 medications in patients seeking substantial weight reduction
US$ 21.24
US$ 20.12
US$ 27.56
US$ 26.35
US$ 29.29
US$ 22.89
US$ 22.41
